FY2025 · ended Dec 31, 2025 · Revenue $90.50M, +8.0% YoY · Filed Mar 10, 2026
Pulmonx Corporation (LUNG) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $90.5 million and a net loss of $54.0 million. Free cash flow was -$32.8 million. As of Sep 30, 2026 it held $52.7 million in cash and investments and $56.4 million in total debt.
Revenue (TTM)
$88.78M
-3.2% vs year-ago TTM
Net income (TTM)
$-42.55M
+25.0% vs year-ago TTM
Operating cash flow (TTM)
$-25.58M
+20.1% vs year-ago TTM
Free cash flow (TTM)
$-25.61M
+21.4% vs year-ago TTM
EPS (TTM)
$-1.01
+28.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
42.24M
+6.1% vs prior year
Net cash
$-3.76M
as of Sep 30, 2026
Operating margin
-44.4%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- LUNG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1127537
- Former names
- PULMONX (until Feb 7, 2012)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $90.5M | $83.8M | $68.7M | $53.7M | $48.4M |
| Operating income | -$53.7M | -$57.7M | -$61.9M | -$58.6M | -$47.3M |
| Net income | -$54.0M | -$56.4M | -$60.8M | -$58.9M | -$48.7M |
| Diluted EPS | -$1.33 | -$1.44 | -$1.60 | -$1.59 | -$1.35 |
| Operating cash flow | -$32.4M | -$31.5M | -$37.6M | -$45.1M | -$41.4M |
| Free cash flow | -$32.8M | -$33.0M | -$38.4M | -$46.4M | -$45.1M |
| Total assets | $129.3M | $162.8M | $177.8M | $193.7M | $235.2M |
| Total liabilities | $75.2M | $77.0M | $59.5M | $39.7M | $41.9M |
| Stockholders' equity | $54.1M | $85.8M | $118.3M | $154.0M | $193.2M |
| Cash and investments | $69.8M | $70.9M | $83.5M | $147.1M | $191.0M |
| Total debt | $56.5M | $59.6M | $43.6M | $24.4M | $26.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
All 450 Pulmonx Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.